Top Markets
Coin of the day
Hemab Therapeutics Holdings, Inc. Common Stock Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

COAG
株式のランク #21709
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm... Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
株価
$50.82
最終同期: 2026-08-11
時価総額
$102.09M
変化(1日)
1.90%
変化(1年)
-
US
取引 Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

カテゴリー

Hemab Therapeutics Holdings, Inc. Common Stock(COAG)の配当利回りの履歴
Hemab Therapeutics Holdings, Inc. Common Stock(銘柄コード: COAG)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Hemab Therapeutics Holdings, Inc. Common Stock(COAG)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)